Trade Tracker: Rob Sechan details his latest portfolio moves

Rob, you have several moves as well. You trimmed Lily, you trimmed Broadcom and you trimmed wells and you sold Comcast, our parent. You can hang up your mic and head out to the back alley. Somebody will be meeting you back there, the trims of Lily, Broadcom and and Wells. So all performance based, I mean these, the two of these stocks are stocks that are up well north of 100% for us in in a very short order. We’re still overweight the stocks. It’s just right sizing the positions Wells, Wells a little different, there’s some and I am a net interest margin pressures and you know they’re investing deeply in the wealth management business which we think could pressure profitability. So we’ve reduced it a bit. Do you not like the banks here We we like JP and Wells frankly Wells is one of our holdings, it’s just a just a trim. So those are our two favorite. It’s performed remarkably since we’ve added it Comcast the parent of this network. Actually this is a tough one. This is a, this is a tax law simply to offset for you if you have a lemon in your throat, right. Wait, Rob, we might have breaking ahead. It’s more, it’s more like a cantaloupe that I have in my throat right now. But anyway, yeah, we’re, we’re taking some tax losses for all the gains that we’re taking in the portfolio. OK. And you bought ABV, you bought IBM 3M and Deckers. Yeah. So last week all of those. Right. All of those. We really made some big purchases here. Decker’s solid retail company, obviously Teva Uggs. Hoka Hoga sneakers. Not cheap, trades at 27 times, but it’s two times the profitability of anybody else. IBM, attractive valuation, healthy dividend yield, diversified revenue mix, but we like to focus on AI and consulting services in the business segment. When you look at three M, this is all about Bill Brown, this a, this a turnaround. This is a company that trades in 11 times PE we believe in it. The cut of the dividend, the 3% was a prudent move and their leverage to global manufacturing activities. So that’s great. And then AB again attractive valuation, most one of the most profitable pharma businesses, huge operating margins. Huge free cash flow margins and more importantly a really robust pipeline. Of therapeutics and and and other drugs that are targeting serious diseases. There’s things to do in this market that aren’t as expensive that have tremendous either turn around or growth opportunity and we’re repositioning the portfolio as such, all right.